Navigation Links
Experimental Vaginal Gel Doesn't Ward Off HIV
Date:12/4/2008

South African women using Carraguard had no decrease in infections, trial found

THURSDAY, Dec. 4 (HealthDay News) -- A microbicidal vaginal gel called Carraguard doesn't protect women from HIV infection.

That's the conclusion of a study that included more than 6,200 sexually-active, HIV-negative women at three sites in South Africa.

The women were given either Carraguard or a placebo gel and told to use one applicator of gel and a condom each time they had vaginal sex. The women, who were followed for up to two years, visited a clinic every three months to have tests for HIV infection and pregnancy, pelvic examinations, risk reduction counseling, and treatment for curable sexually transmitted diseases and vaginal infections.

The rate of HIV infection among women using Carraguard was 3.3 per 100-woman years, compared with 3.8 per 100-woman years in the placebo group. Rates of self-reported gel use were similar in both groups (96.2 percent Carraguard, 95.9 percent placebo), but applicator testing indicated that actual gel use was much lower (41.1 percent Carraguard, 43.1 percent placebo). Self-reported condom use was 64.1 percent for both groups.

The findings were published in this week's issue of The Lancet.

"This study did not show Carraguard's efficacy in prevention of male-to-female transmission of HIV, although no safety concerns were recorded. Low levels of gel use could have compromised the potential to detect a significant protective effect. Although the results from this and other completed microbicide efficacy trials have been disappointing, the search for female-controlled HIV-prevention methods must continue," wrote researchers from the Population Council in New York City and their colleagues.

Carraguard, a carrageenan-based compound, was developed by the Population Council.

In an accompanying comment, Dr. Willard Cates and Dr. Paul Feldblum, of Family Health International in North Carolina, wrote that no single method of HIV prevention will be adequate.

"Rather a combination of partly effective prevention approaches will be bundled into packages targeted to specific populations. This bundling will involve behavioral, biomedical, and structural interventions, each designed to reinforce the effect of the other. The cumulative influence of combination prevention is our hope for thwarting the spread of HIV," they said.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV infection risk factors and prevention.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaginal Gel Doesn't Ward Off HIV
(Date:2/22/2017)... Burlingame, CA (PRWEB) , ... February 22, 2017 ... ... of American adults with chronic conditions reported skipping doses or not filling a ... were uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
(Date:2/22/2017)... Singapore (PRWEB) , ... February 22, 2017 , ... Using ... medical leads utilizing a simple online checklist. Over a period of just 24 months, ... the assistance of an online checklist called T.A.D. , “The internet is not getting ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus ... the latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems ... pain management, to accelerate tissue synthesis and provide a faster and more efficient ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s ... different solutions on the market, it is easy to start feeling frustrated and ... offers a complimentary security consultation. , Home Security Hardware Choices, There are ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb 22, 2017 Research and Markets ... Analysis & Trends - Industry Forecast to 2025" report to their ... The Global Clot ... 5.2% over the next decade to reach approximately $2.1 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... Trend Indicator):Analysis By Region, By Country (2016-21)" report to their ... Global ... CAGR of 5.33% during 2016-2021 The strong growth is ... demand of digital thermometer. Apart from that, the downfall in the ...
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
Breaking Medicine Technology: